

Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-PM 4968	SERIAL NO. 09/976,451
	APPLICANT: Braun et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: 10/12/2001	GROUP: 1645

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
~		6,309,643	10/30/01	Braun et al.	—	—	
~		6,033,864	03/07/00	Braun et al.	—	—	

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANS-L ATION YES/NO
~		WO 00/66067	11/09/2000	PCT	—	—	
~		WO 99/45955	09/19/1999	PCT	—	—	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

~		Abe et al., "Clinical role for a superantigen in <i>Yersinia pseudotuberculosis</i> infection," <u>J. Clin. Invest.</u> 99:1823-1830 (1997).
~		Ambrose et al., "Antibiotic therapy for treatment in relapse of intestinal Crohn's disease. A prospective randomized study," <u>Dis. Colon Rectum</u> 28:81-85 (1985).
~		Aranda et al, "Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4 ⁺ , CD45RB ^{high} T cells to SCID recipients," <u>J. Immunol.</u> 158:3464-3473 (1997).

EXAMINER MARK NAVARRO	DATE CONSIDERED 1/6/04
------------------------------	-------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-PM 4968	SERIAL NO. 09/976,451
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT: Braun et al.	GROUP: 1645

~	Blaser et al., "Patients With Active Crohn's Disease Have Elevated Serum Antibodies to Antigens of Seven Enteric Bacterial Pathogens," <u>Gastroenterology</u> 87:888-894 (1984).
~	Blumberg et al., "Animal models of mucosal inflammation and their relation to human inflammatory bowel disease," <u>Curr. Opin. Immunol.</u> 11:648-656 (1999).
~	Brandwein et al., "Spontaneously colitic C3H/HeJBir mice demonstrate selective antibody reactivity to antigens of the enteric bacterial flora," <u>J. Immunol.</u> 159:44-52 (1997).
~	Bregenholt et al., "T-cell transfer and cytokine TCR gene deletion models in the study of inflammatory bowel disease," <u>APMIS</u> 105:655-662 (1997).
~	Brennan et al., "Pseudomonas aeruginosa outer-membrane protein F epitopes are highly immunogenic in mice when expressed on a plant virus," <u>Microbiology</u> 145:211-20 (1999).
~	Cachia et al., "The use of synthetic peptides in the design of a consensus sequence vaccine for <i>Pseudomonas aeruginosa</i> ," <u>J. Pept. Res.</u> 52:289-99 (1998).
~	Callanan et al., "Regulation of the iron uptake genes in <i>Pseudomonas fluorescens</i> M114 by pseudobactin M114:the pbrA sigma factor gene does not mediate the siderophore regulatory response," <u>FEMS Microbiol. Lett.</u> 144:61-66 (1996).
~	Campbell et al., "Interaction of the receptor binding domains of <i>Pseudomonas aeruginosa</i> pili strains PAK, PAO, KB7 and P1 to a cross-reactive antibody and receptor analog: implications for synthetic vaccine design," <u>J. Mol. Biol.</u> 267:382-402 (1997).

EXAMINER MARK NABARO	DATE CONSIDERED 1/6/04
-------------------------	---------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-PM 4968	SERIAL NO. 09/976,451
	APPLICANT: Braun et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: 10/12/2001	GROUP: 1645

~	Cellier et al., "Mycobacterium paratuberculosis and Mycobacterium avium subsp. silvaticum DNA cannot be detected by PCR in Crohn's disease tissue," <u>Gastroenterol. Clin. Biol.</u> 22:675-678 (1998).
~	Chen et al., "Recombinant protein composed of Pseudomonas exotoxin A, outer membrane proteins I and F as vaccine against P. aeruginosa infection," <u>Appl. Microbiol. Biotechnol.</u> 52:524-33 (1999).
~	Chiba et al., "No Mycobacterium paratuberculosis detected in intestinal tissue, including Peyer's patches and lymph follicles, of Crohn's disease," <u>J. Gastroenterology</u> 33:482-487 (1998).
~	Cho-Chung, "Antisense oligonucleotide inhibition of serine/threonine kinases: an innovative approach to cancer treatment," <u>Pharmacol. Ther.</u> 82:437-449 (1999).
~	Clarkston et al., "Role of Mycobacterium Paratuberculosis in Crohn's Disease," <u>Dis. Colon Rectum</u> 41:195-199 (1998).
~	Cocito et al., "Paratuberculosis," <u>Clinical Microbiology Reviews</u> 7:328-345 (1994).
~	Cong et al., "CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: Increased T helper cell type 1 response and ability to transfer disease," <u>J. Exp. Med.</u> 187:855-864 (1998).
~	Cripps et al., "Vaccine strategies against Pseudomonas aeruginosa infection in the lung," <u>Behring Inst. Mitt.</u> 98:262-268 (1997).
~	Cryz et al., "Synthesis and characterization of a polyvalent Escherichia coli O-polysaccharide-toxin A conjugate vaccine," <u>Vaccine</u> 13:449-453 (1995).

EXAMINER MARK NAVARRO	DATE CONSIDERED 1/6/04
--------------------------	---------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-PM 4968	SERIAL NO. 09/976,451
	APPLICANT: Braun et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: 10/12/2001	GROUP: 1645

~	Dalwadi et al., "Identification of a novel IBD-Associated microbial agent by representational difference analysis," <u>Gastroenterology</u> 116(4): A696 AGA Abstracts (1999).
~	Dalwadi et al., "The Crohn's disease-associated bacterial protein, I2, is a novel enteric T cell superantigen" <u>Immunity</u> 15:149-58 (2001).
~	Del Prete et al., "Detection of <i>Mycobacterium paratuberculosis</i> in stool samples of patients with inflammatory bowel disease by IS900-based PCR and colorimetric detection of amplified DNA," <u>J. Microbiol. Methods</u> 33:105-114 (1998).
~	Dianda et al., "T cell receptor- $\alpha\beta$ -deficient mice fail to develop colitis in the absence of a microbial environment," <u>Am. J. Pathol.</u> 150:91-97 (1997).
~	Doring and Dorner, "A multicenter vaccine trial using the <i>Pseudomonas aeruginosa</i> flagella vaccine IMMUNO in patients with cystic fibrosis," <u>Behring Inst. Mitt.</u> 98:338-344 (1997).
~	El-Zaatari et al., "Characterization of a Specific <i>Mycobacterium paratuberculosis</i> Recombinant Clone Expressing 35,000-Molecular-Weight Antigen and Reactivity with Sera from Animals with Clinical and Subclinical Johne's Disease," <u>Journal of Clinical Microbiology</u> 35:1794-1799 (1997).
~	Elsaghier et al., "Antibodies to <i>Mycobacterium paratuberculosis</i> -specific protein antigens in Crohn's disease," <u>Clin. Exp. Immunol.</u> 90:503-508 (1992).
~	Epelman et al., " <i>Pseudomonas aeruginosa</i> exoenzyme S induces transcriptional expression of proinflammatory cytokines and chemokines," <u>Infect. Immun.</u> 68:4811-4814 (2000).

EXAMINER MARK NAWARD	DATE CONSIDERED 1/6/04
-------------------------	---------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-PM 4968	SERIAL NO. 09/976,451
	APPLICANT: Braun et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: 10/12/2001	GROUP: 1645

~	Fidler et al., "Specific detection of <i>Mycobacterium paratuberculosis</i> DNA associated with granulomatous tissue in Crohn's disease," <u>Gut</u> 35:506-510 (1994).
~	Finegold and Sutter, "Fecal flora in different populations, with special reference to diet," <u>Am. J. Clin. Nutr.</u> 31:S116-S122 (1978).
~	Finegold et al., "Fecal microbial flora in Seventh Day Adventist populations and control subjects," <u>Am. J. Clin. Nutr.</u> 30:1781-1792 (1977).
	GenBank Accession No.: AF173683.2 - Pseudomonas fluorescens putative transcriptional regulator Pfi2 and DbrA like transcriptional activator gene, complete cds; and unknown genes. NO PUBLIC AVAILABILITY DATE
	GenBank Accession No.: AF173683.1 - Bacterium T2 unknown gene. NO PUBLIC AVAILABILITY DATE
~	Gilleland et al., "Use of synthetic peptides to identify surface-exposed, linear B-cell epitopes within outer membrane protein F of <i>Pseudomonas aeruginosa</i> ," <u>Curr. Microbiol.</u> 31:279-86 (1995).
~	Gionchetti et al., "Review - antibiotic treatment in inflammatory bowel disease: rifaximin, a new possible approach," <u>Eur. Rev. Med. Pharmacol. Sci.</u> 3:27-30 (1999).
~	Graham et al., "DNA hybridization studies of the association of <i>Pseudomonas maltophilia</i> with inflammatory bowel diseases," <u>J. Lab. Clin. Med.</u> 101:940-954 (1983).
~	Gui et al., "Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics," <u>J. Antimicrob. Chemother.</u> 39:393-400 (1997).

EXAMINER MARK NAVARRO	DATE CONSIDERED 1/6/04
--------------------------	---------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-PM 4968	SERIAL NO. 09/976,451
	APPLICANT: Braun et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: 10/12/2001	GROUP: 1645

~	Ichikawa et al., "Interaction of <i>Pseudomonas aeruginosa</i> with epithelial cells: Identification of differentially regulated genes by expression microarray analysis of human cDNAs," <u>Proc. Natl. Acad. Sci. USA</u> 97:9659-9664 (2000).
~	Jang et al., "Human immune response to a <i>Pseudomonas aeruginosa</i> outer membrane protein vaccine," <u>Vaccine</u> 17:158-68 (1999).
~	Janowitz et al., "The role of the fecal stream in Crohn's disease: An historical and analytic review," <u>Inflamm. Bowel Dis.</u> 4:29-39 (1998).
~	Ji et al., "Identification of Critical Staphylococcal Genes Using Conditional Phenotypes Generated by Antisense RNA," <u>Science</u> 293:2266-2269 (2001).
~	Juliano and Yoo, "Aspects of the transport and delivery of antisense oligonucleotides," <u>Curr. Opin. Mol. Ther.</u> 2:297-303 (2000).
~	Knapp et al., "A recombinant hybrid outer membrane protein for vaccination against <i>Pseudomonas aeruginosa</i> ," <u>Vaccine</u> 17:1663-1666 (1999).
~	Koukalova et al., "Development of a vaccine for treatment of urinary tract inflammatory diseases," <u>Bratisl. Lek. Listy</u> 100:92-5 (1999)
~	Lang et al., "Effect of high-affinity anti- <i>Pseudomonas aeruginosa</i> lipopolysaccharide antibodies induced by immunization on the rate of <i>Pseudomonas aeruginosa</i> infection in patients with cystic fibrosis," <u>J. Pediatr.</u> 127:711-717 (1995).

EXAMINER MARK NUNO	DATE CONSIDERED 1/6/04
-----------------------	---------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-PM 4968	SERIAL NO. 09/976,451
	APPLICANT: Braun et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: 10/12/2001	GROUP: 1645

~	Langholz et al., "Treatment of Crohn's disease with fusidic acid: An antibiotic with immunosuppressive properties similar to cyclosporin," <u>Aliment Pharmacol. Ther.</u> 6:495-502 (1992).
~	Lee et al., "Conformation-dependent antibody response to <i>Pseudomonas aeruginosa</i> outer membrane proteins induced by immunization in humans," <u>FEMS Immunol. Med. Microbiol.</u> 27:79-85 (2000).
~	Lee et al., "Immunization of burn-patients with a <i>Pseudomonas aeruginosa</i> outer membrane protein vaccine elicits antibodies with protective efficacy," <u>Vaccine</u> 18:1952-61 (2000).
~	Leoni et al., "Functional analysis of PvdS, an iron starvation sigma factor of <i>Pseudomonas aeruginosa</i> ," <u>J. Bacteriol.</u> 182:1481-1491 (2000).
~	Lewin and Hauswirth, "Ribozyme gene therapy: Applications for molecular medicine," <u>Trends. Mol. Med.</u> 7:221-228 (2001).
~	Li et al., "The structural basis of T cell activation by superantigens," <u>Annu. Rev. Immunol.</u> 17:435-466 (1999).
~	Lister et al., " β -lactamase inhibitor combinations with extended-spectrum penicillins: Factors influencing antibacterial activity against enterobacteriaceae and <i>Pseudomonas aeruginosa</i> ," <u>Pharmacotherapy</u> 20:213S-218S (2000).
~	Mansouri et al., "Safety and immunogenicity of a <i>Pseudomonas aeruginosa</i> hybrid outer membrane protein F-I vaccine in human volunteers," <u>Infect. Immun.</u> 67:1461-70 (1999).
~	Marrack and Kappler, "Subversion of the immune system by pathogens," <u>Cell</u> 76:323-332 (1994).

EXAMINER MARK NAVARRO	DATE CONSIDERED 1/6/04
--------------------------	---------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-PM 4968	SERIAL NO. 09/976,451
	APPLICANT: Braun et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: 10/12/2001	GROUP: 1645

~	Martin and Rohodes, "Bacteria and inflammatory bowel disease," <u>Curr. Opin. Infect. Dis.</u> 13:503-509 (2000).
~	Moss et al., "Polymerase chain reaction detection of <i>Mycobacterium paratuberculosis</i> and <i>Mycobacterium avium</i> subsp <i>silvaticum</i> in long term cultures from Crohn's disease and control tissues," <u>Gut</u> 33:1209-1213 (1992).
~	Parent and Mitchell, "Cell wall-defective variants of <i>Pseudomonas</i> -like (group Va) bacteria in Crohn's disease," <u>Gastroenterology</u> 75:368-372 (1978).
~	Parent and Mitchell, "Bacterial variants: Etiologic agent in Crohn's disease?," <u>Gastroenterology</u> 71:365-368 (1976).
~	Park et al., "General pharmacology of a <i>Pseudomonas</i> vaccine prepared from outer-membrane fractions of <i>Pseudomonas aeruginosa</i> ," <u>Arzne-Forsch/Drug Res.</u> 46(II):1001-6 (1996).
~	Podolsky, "Lessons from genetic models of inflammatory bowel disease," <u>Acta Gastro-Enterol. Belg.</u> 60:163-165 (1997).
~	Powrie et al., "Inhibition of Th1 Responses Prevents Inflammatory Bowel Disease in scid Mice Reconstituted with CD45RB ^{hi} CD4 ⁺ T Cells," <u>Immunity</u> 1:553-562 (1994).
~	Prantera et al., "Antimycobacterial therapy in Crohn's disease: Results of a controlled, double-blind trial with a multiple antibiotic regime," <u>Am. J. Gastroenterol.</u> 89:513-518 (1994).
~	Prantera et al., "An Antibiotic Regimen for the Treatment of Active Crohn's Disease: A Randomized, controlled Clinical Trial of Metronidazole plus Ciprofloxacin," <u>Am. J. Gastroenterol.</u> 91:328-332 (1996).

EXAMINER MARK NAVARRO	DATE CONSIDERED 1/6/04
--------------------------	---------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-PM 4968	SERIAL NO. 09/976,451
	APPLICANT: Braun et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: 10/12/2001	GROUP: 1645

~	Rawling and Martin, "Epitope mapping of the <i>Pseudomonas aeruginosa</i> major outer membrane porin protein OprF," <u>Infect. Immun.</u> 63:38-42 (1995).
~	Sanderson et al., "Mycobacterium paratuberculosis DNA in Crohn's disease tissue," <u>Gut</u> 33:890-896 (1992).
~	Seibold et al., "pANCA Represents a Cross-Reactivity to Enteric Bacterial Antigens," <u>Journal of Clinical Immunology</u> 18:153-160 (1998).
~	Sendid et al., "Specific antibody response to oligomannosidic epitopes in Crohn's disease," <u>Clin. Diag. Lab. Immunol.</u> 3:219-226 (1996).
~	Sexton et al., "Transcriptional regulation of the iron-responsive sigma factor gene <i>pbrA</i> ," <u>Mol. Gen. Genet.</u> 250:50-58 (1996).
~	Sexton et al., "Iron-responsive gene expression in <i>Pseudomonas fluorescens</i> M114: cloning and characterization of a transcription-activating factor, <i>PbrA</i> ," <u>Mol. Microbiol.</u> 15:297-306 (1995).
~	Sheth et al., "Development of an anti-adhesive vaccine for <i>Pseudomonas aeruginosa</i> targeting the C-terminal region of the pilin structural protein," <u>Biomed. Pept. Proteins Nucleic Acids</u> 1:141-8 (1995).
~	Siegel et al., "Parathyroid hormone stimulates dephosphorylation of the renoredoxin component of the 25-hydroxyvitamin D ₃ -1 α -hydroxylase from rat renal cortex," <u>J. Biol. Chem.</u> 261:16998-17003 (1986).
~	Sonnenberg, "Occupational distribution of inflammatory bowel disease among German employees," <u>Gut</u> 31:1037-1040 (1990).

EXAMINER MARK NAVARRO	DATE CONSIDERED 1/6/04
--------------------------	---------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.




PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-PM 4968	SERIAL NO. 09/976,451
	APPLICANT: Braun et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: 10/12/2001	GROUP: 1645

~	Stanislavsky et al., "Antigenic and Protective Properties of Lipopolysaccharides of R-Forms of some grame-negative bacteria," <u>Zh. Mikrobiol. Epidemiol. Immunobiol.</u> 52-56 (1998).
~	Stanislavsky and Lam, "Pseudomonas aeruginosa antigens as potential vaccines," <u>FEMS Microbiol. Rev.</u> 21:243-77 (1997).
~	Stanislavsky et al., "R-form lipopolysaccharides (LPS) of Gram-negative bacteria as possible vaccine antigens," <u>FEMS Immunol. Med. Microbiol.</u> 18:139-45 (1997).
~	Stover et al., "Complete genome sequence of <i>Pseudomonas aeruginosa</i> PA01, an opportunistic pathogen," <u>Nature</u> 406:959-964 (2000).
~	Sutton et al., "Identification of a Novel Bacterial Sequence Associated with Crohn's Disease," <u>Gastroenterology</u> 119:23-31 (2000).
~	Thomas et al., "Controlled trial of antituberculous chemotherapy in Crohn's disease: A five year follow up study," <u>Gut</u> 42:497-500 (1998).
~	Vannuffel et al., "Occurrence, in Crohn's Disease, of Antibodies Directed against a Species-Specific Recombinant Polypeptide of <i>Mycobacterium paratuberculosis</i> ," <u>Clinical and Diagnostic Laboratory Immunology</u> 1:241-243 (1994).
~	von Specht et al., "Outer membrane proteins of <i>Pseudomonas aeruginosa</i> as vaccine candidates," <u>J. Biotechnol.</u> 44:145-53 (1996).
~	von Specht, "A new vaccine against <i>P. aeruginosa</i> infections. Based on recombinant <i>P. aeruginosa</i> outer membrane proteins," <u>Zentralbl. Chir.</u> 124:298-302 (1999).

EXAMINER MARK NAVARRO	DATE CONSIDERED 1/6/04
--------------------------	---------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-PM 4968	SERIAL NO. 09/976,451
	APPLICANT: Braun et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: 10/12/2001	GROUP: 1645

~	Wang et al., "Overexpression of murine <i>fizzy-related (fzr)</i> increases natural killer cell-mediated cell death and suppresses tumor growth," <u>Blood</u> 96:259-263 (2000).
~	Wayne et al., "Immunoglobulin A (IgA) and IgG Serum Antibodies to Mycobacterial Antigens in Crohn's Disease Patients and Their Relatives," <u>J. Clin. Microbiology</u> 30:2013-2018 (1992).
~	Weiner et al., "Oral Tolerance: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," <u>Ann. Rev. Immunol.</u> 12:809-837 (1994).
~	Weiner, "Oral Tolerance: Mobilizing the Gut," <u>Hospital Practice</u> September 15th, pp. 53-58 (1995).
~	Wilson et al., "Phylogenetic placement of community members of human colonic biota," <u>Clin. Infect. Dis.</u> 25(S2):S114-S116 (1997).
~	Wilson et al., "Analysis of promoters recognized by PvdS, an extracytoplasmic-function sigma factor protein from <i>Pseudomonas aeruginosa</i> ," <u>J. Bacteriol.</u> 183:2151-2155 (2001).
~	Xiong et al., "The oxygen- and iron-dependent sigma factor <i>pvdS</i> of <i>Pseudomonas aeruginosa</i> is an important virulence factor in experimental infective endocarditis," <u>J. Infect. Dis.</u> 181:1020-1026 (2000).
~	Yamaguchi et al., "Activities of antimicrobial agents against 5,180 clinical isolates obtained from 26 medical institutions during 1998 in Japan. Levofloxacin-Surveillance Group," <u>Japanese J. Antibiot.</u> 53:387-408 (1998).

EXAMINER MARK NAVARRO	DATE CONSIDERED 1/6/04
--------------------------	---------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.